Cisen Pharmaceutical released its 2026 half-year report. Net profit attributable to the parent in the first half was 264 million yuan, up 15.4% year on year. Operating revenue was 1.69 billion yuan, down 2.7% year on year. Net profit attributable to the parent after deducting non-recurring items was 158 million yuan, down 12.0% year on year. Net operating cash flow was 427 million yuan, up 20.9% year on year. Second-quarter net profit attributable to the parent was 134 million yuan, up 56.2% year on year. The company said overall operations were stable, with its main business still concentrated in the pharmaceutical manufacturing industry.
Cisen Pharmaceutical Co LtdNet profit attributable to parent rose 15.4% YoY, with Q2 profit up 56.2%.
